MedLumics announced raising €18 million from Kurma, Asabys and Caixa.
MedLumics, a Madrid, Spain-based medical deveice manufacturer, announced that it secured a funding round of €18 million ($21.8M).
The money was raised from investors from Switzerland, France, Spain and Italy, including Kurma Partners, VI Partners Swiss Innovation, CDTI, Asabys Partners, Andera Partners, Caixa Capital Risc and Innogest.
The company also announced that it appointed Rich Ferrari as Chairman of the Board of Directors. Current President Olivier Litzka of Andera Partners will take over as Vice President.
MedLumics will use the funds to initiate the first regulatory clinical trials in humans and automate the manufacture of scalable products after achieving preclinical viability in 2020.
MedLumics, founded in 2009 and led by James Greene (CEO), developed a device called Ablaview, an irrigated radiofrequency cardiac ablation system that combines photonics and minimally invasive optical instruments to guide catheter positioning and determine injury in real time. AblaView is the first imaging system to assess the treatment of atrial fibrillation by ablation, allowing clinicians to determine catheter positioning, contact stability, and transmurality of the lesion during tissue ablation.
MedLumics previously raised €14M in 2020.